微生物検査/臨床微生物の世界市場規模：製品タイプ別、用途別、エンドユーザー別、地域別、範囲および予測

微生物検査/臨床微生物の市場規模と予測

微生物検査/臨床微生物市場規模は、2024年に61億5,000万米ドルと評価され、2024年から2031年にかけて10.17%のCAGRで成長し、2031年には133億4,000万米ドルに達すると予測されています。臨床微生物学としても知られる微生物検査は、微生物学分野の一分野であり、微生物と人間の健康や病気との相互作用の研究に焦点を当てています。臨床微生物学では、臨床検体から検出された細菌、ウイルス、真菌、寄生虫などの微生物の同定と特性解析を行う。これは感染症の診断や適切な治療戦略の決定に役立ちます。血液、尿、喀痰、組織などの臨床検体中の微生物を検出し、定量するためのさまざまな診断検査が含まれます。その手法は、従来の培養法から、迅速かつ正確な診断のための分子生物学的、免疫学的アッセイまで多岐にわたります。

微生物検査には、抗生物質やその他の抗菌剤に対する微生物の感受性の評価も含まれます。これにより、臨床医は最も効果的な治療法を知ることができ、抗菌薬耐性との戦いに役立ちます。

臨床微生物学は、感染症の発生を特定し、疾患の動向を追跡し、ヘルスケア環境における感染症の蔓延を抑えるための予防策を実施することで、感染管理および疫学サーベイランスにおいて重要な役割を果たしています。

また、感染症、ワクチン開発、抗菌療法などの研究開発にも貢献しています。微生物検査は、感染症の病因に関する貴重な洞察を提供し、新しい診断ツールや治療法の開発に役立ちます。

臨床微生物検査室は、検査結果の正確性と信頼性を保証するために、厳格な品質保証の実践と規制基準を遵守しています。これには、検査手法の習熟度の維持、外部品質評価プログラムへの参加、検査施設認定要件の遵守などが含まれます。

世界の微生物検査／臨床微生物市場力学

世界の微生物検査／臨床微生物市場を形成している主な市場力学

主な市場促進要因

感染症の発生率の増加

細菌感染、ウイルス感染、真菌感染、寄生虫感染など、感染症の世界の流行増加は、これらの症状を正確に診断し治療するための微生物検査に対する需要を促進しています。

検査法の技術的進歩

分子診断、次世代シーケンシング（NGS）、自動化システムなど、微生物検査法の絶え間ない技術革新により、微生物の検出・同定の精度、スピード、効率が向上しています。

高まる意識と早期診断の重視

医療従事者や患者の間では、感染症の早期診断と迅速な治療の重要性に対する認識が高まっています。このため、タイムリーな介入を促進し、患者の転帰を改善する微生物検査に対する需要が高まっています。

ヘルスケア支出の増加

世界のヘルスケア支出の増加は、高度な診断技術と微生物検査ラボのインフラへの投資を支え、市場の成長を促進します。

抗菌薬耐性（AMR）の懸念

世界の抗菌薬耐性の課題の高まりにより、微生物検査による耐性パターンの効果的な監視とモニタリングが必要となっています。このため、適切な治療方針を決定するための抗菌薬感受性試験（AST）や分子タイピングの需要が高まっています。

ポイントオブケア検査（POCT）の拡大

ポイントオブケアにおける検査の分散化と迅速診断の動向は、微生物検査POCT機器の採用を促進し、迅速なターンアラウンドタイムと患者管理の改善を可能にします。

世界化と旅行関連感染症

世界の旅行や移住の増加は、国境を越えた感染症の蔓延を助長しており、サーベイランス、アウトブレイク管理、公衆衛生への対応に堅牢な微生物検査機能が必要とされています。

規制サポートと標準

微生物検査施設の品質保証と認定のための支持的な規制の枠組みと基準は、検査結果の信頼性と信用性を高め、市場の成長を促進します。

主な課題：

新興感染症

新しい病原体や感染症の急速な出現は、タイムリーな診断検査の開発や、新規微生物の検出に既存の検査法を適応させる上での課題となっています。

抗菌薬耐性（AMR）

抗菌薬に対する微生物の耐性の増加は、治療方針の決定を複雑にし、耐性パターンを効果的に検出・監視するために微生物学的検査法の継続的な適応を必要とします。

複雑なサンプルマトリックス

臨床検体は、その複雑さや組成が様々であり、微生物学的検査の感度と特異性に影響を与えます。課題としては、サンプル調製、宿主物質からの干渉、病原体を分離・同定するための特殊技術の必要性などが挙げられます。

技術的限界

微生物検査技術は進歩しているが、診断アッセイの感度、特異性、迅速性の向上には課題が残っています。堅牢な分子および次世代シーケンサー・プラットフォームの開発には、継続的な研究と投資が必要です。

品質保証と標準化

高水準の品質保証を維持し、微生物検査法や検査室間の一貫性を確保することは課題です。技能試験、機器の校正、規制要件の遵守におけるばらつきは、検査結果の信頼性に影響を与える可能性があります。

コストと償還のプレッシャー

高度な微生物検査技術、試薬、機器のコストは、ヘルスケア施設、特に資源が限られた環境では、高額になる可能性があります。償還の課題と費用対効果の考慮が、新しい検査手法の普及を制限する可能性があります。

人材不足とトレーニングの必要性

微生物学者、検査技師、分子生物学者など、臨床微生物学分野の熟練労働者は不足しています。高度な診断技術の使用や複雑な検査結果の解釈に習熟するためには、継続的なトレーニングと教育が不可欠です。

データ管理と統合

ゲノムデータ、患者情報、疫学データを含む大量の微生物学データの効果的な管理と統合は、臨床および公衆衛生環境において十分な情報に基づいた意思決定を行うためのデータの保存、分析、解釈における課題です。

主な動向

分子診断学へのシフト

PCR（ポリメラーゼ連鎖反応）、核酸増幅検査（NAAT）、次世代シークエンシング（NGS）など、病原体や抗菌薬耐性マーカーを迅速かつ正確に同定するための分子診断技術の採用が増加しています。

自動化とロボティクス

検体の取り扱い、培養、感受性試験など、微生物学的検査プロセスの自動化が進んでいます。ロボット工学と自動化システムは、ワークフローを合理化し、納期を改善し、検査室の効率を高めます。

ポイント・オブ・ケア検査（POCT）

微生物学におけるポイント・オブ・ケア検査技術の拡大により、ベッドサイドや遠隔地での迅速な診断と治療方針の決定が可能になります。感染症診断のためのPOCT機器はより洗練され、利用しやすくなっています。

人工知能（AI）の統合

データ解析、複雑な微生物パターンの解釈、抗菌薬耐性の予測のために、AI主導のアルゴリズムが微生物検査プラットフォームに統合されつつあります。AIは診断精度を高め、結果を迅速化し、個別化された治療アプローチをサポートします。

抗菌薬感受性試験（AST）の進歩

自動化システムや迅速な表現型検査を含むAST手法の革新により、抗菌薬感受性プロファイルの精度が向上します。これらの進歩は、抗生物質治療の最適化と抗菌薬耐性菌対策に役立っています。

マルチプレックス検査の台頭

複数の病原体や耐性遺伝子を同時に検出できるマルチプレックス・アッセイが人気を集めています。これらの検査は診断効率を高め、納期を短縮し、包括的な感染症管理をサポートします。

デジタル化と接続性

検査室情報管理システム（LIMS）や電子カルテ（EHR）などの微生物検査室向けデジタルソリューションは、シームレスなデータ管理、結果報告、ヘルスケアシステムとの統合を促進し、患者ケアの向上を実現します。

感染症サーベイランスと疫学に焦点

微生物学的データを用いたリアルタイムの感染症サーベイランスが重視されるようになっています。ゲノムシーケンスと疫学情報の統合は、疾病発生の追跡、動向のモニタリング、公衆衛生介入の実施に役立ちます。

個別化医療のアプローチ

遺伝的感受性や微生物プロファイルなど、個々の患者の特性に基づいて抗菌薬療法を調整することが普及しつつあります。微生物学的検査は、個別化された治療方針を導き、患者の転帰を改善する上で重要な役割を果たします。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 微生物検査/臨床微生物市場：製品タイプ別

• 臨床診断
• 食品検査
• 医薬品・バイオテクノロジー用途
• 環境検査

第5章 微生物検査/臨床微生物市場：用途別

• 検査機器
• 試薬・キット
• 消耗品
• ソフトウェアとサービス

第6章 微生物検査/臨床微生物市場：エンドユーザー別

• 病院・診断研究所
• 飲食品会社
• 製薬・バイオテクノロジー企業
• 環境試験研究所

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Abbott Laboratories
• Becton, Dickinson and Company（BD）
• Danaher Corporation（through its subsidiary Beckman Coulter）
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Illumina, Inc.
• Merck KGaA, Darmstadt, Germany
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Microbiology Testing/Clinical Microbiology Market Size And Forecast

Microbiology Testing/Clinical Microbiology Market size was valued at USD 6.15 Billion in 2024 and is projected to reach USD 13.34 Billion by 2031, growing at a CAGR of 10.17% from 2024 to 2031. Microbiology testing, also known as clinical microbiology, is a branch of microbiology focused on the study of microorganisms and their interactions with human health and disease. Clinical microbiology involves the identification and characterization of microorganisms such as bacteria, viruses, fungi, and parasites found in clinical specimens. This helps in diagnosing infectious diseases and determining appropriate treatment strategies. It encompasses a variety of diagnostic tests to detect and quantify microorganisms in clinical samples, including blood, urine, sputum, and tissues. Techniques range from traditional culture methods to molecular and immunological assays for rapid and accurate diagnosis.

Microbiology testing includes assessing the susceptibility of microorganisms to antibiotics and other antimicrobial agents. This informs clinicians about the most effective treatment options and helps combat antimicrobial resistance.

Clinical microbiology plays a crucial role in infection control and epidemiological surveillance by identifying outbreaks, tracking disease trends, and implementing preventive measures to limit the spread of infectious diseases in healthcare settings.

It contributes to research and development in the field of infectious diseases, vaccine development, and antimicrobial therapies. Microbiology testing provides valuable insights into the pathogenesis of infections and informs the development of new diagnostic tools and treatments.

Clinical microbiology laboratories adhere to stringent quality assurance practices and regulatory standards to ensure the accuracy and reliability of test results. This includes maintaining proficiency in testing methodologies, participating in external quality assessment programs, and complying with laboratory accreditation requirements.

Global Microbiology Testing/Clinical Microbiology Market Dynamics

The key market dynamics that are shaping the global microbiology testing/clinical microbiology market include:

Key Market Drivers

Increasing Incidence of Infectious Diseases

: The rising prevalence of infectious diseases worldwide, including bacterial, viral, fungal, and parasitic infections, drives demand for microbiology testing to accurately diagnose and treat these conditions.

Technological Advancements in Testing Methods

: Continuous innovation in microbiology testing methods, such as molecular diagnostics, next-generation sequencing (NGS), and automated systems, enhances the accuracy, speed, and efficiency of microbial detection and identification.

Growing Awareness and Emphasis on Early Diagnosis

: There is increasing awareness among healthcare providers and patients about the importance of early diagnosis and prompt treatment of infectious diseases. This drives demand for microbiology testing to facilitate timely intervention and improve patient outcomes.

Rising Healthcare Expenditure

: Increased healthcare spending globally supports investment in advanced diagnostic technologies and infrastructure for microbiology testing laboratories, fostering market growth.

Antimicrobial Resistance (AMR) Concerns

: The growing challenge of antimicrobial resistance worldwide necessitates effective surveillance and monitoring of resistance patterns through microbiology testing. This drives demand for antimicrobial susceptibility testing (AST) and molecular typing to guide appropriate treatment decisions.

Expansion of Point-of-Care Testing (POCT)

: The trend towards decentralized testing and rapid diagnostics at point of care settings promotes the adoption of microbiology POCT devices, enabling quicker turnaround times and improved patient management.

Globalization and Travel-Related Infections

: Increased global travel and migration contribute to the spread of infectious diseases across borders, necessitating robust microbiology testing capabilities for surveillance, outbreak management, and public health response.

Regulatory Support and Standards

: Supportive regulatory frameworks and standards for quality assurance and accreditation of microbiology laboratories enhance the reliability and credibility of test results, driving market growth.

Key Challenges:

Emerging Infectious Diseases

: Rapid emergence of new pathogens and infectious diseases poses challenges in developing timely diagnostic tests and adapting existing assays to detect novel microorganisms.

Antimicrobial Resistance (AMR)

: Increasing resistance of microorganisms to antimicrobial agents complicates treatment decisions and requires continuous adaptation of microbiology testing methods to detect and monitor resistance patterns effectively.

Complex Sample Matrix

: Clinical specimens can vary widely in complexity and composition, affecting the sensitivity and specificity of microbiology tests. Challenges include sample preparation, interference from host materials, and the need for specialized techniques to isolate and identify pathogens.

Technological Limitations

: While there have been advancements in microbiology testing technologies, challenges remain in improving the sensitivity, specificity, and speed of diagnostic assays. Development of robust molecular and next-generation sequencing platforms requires ongoing research and investment.

Quality Assurance and Standardization

: Maintaining high standards of quality assurance and ensuring consistency across microbiology testing methods and laboratories is challenging. Variability in proficiency testing, calibration of instruments, and adherence to regulatory requirements can impact the reliability of test results.

Cost and Reimbursement Pressures

: The cost of advanced microbiology testing technologies, reagents, and equipment can be prohibitive for healthcare facilities, especially in resource-limited settings. Reimbursement challenges and cost-effectiveness considerations may limit widespread adoption of new testing methodologies.

Workforce Shortages and Training Needs

: There is a shortage of skilled labor in clinical microbiology, including microbiologists, laboratory technicians, and molecular biologists. Ongoing training and education are essential to ensure proficiency in using advanced diagnostic technologies and interpreting complex test results.

Data Management and Integration

: Effective management and integration of large volumes of microbiology data, including genomic data, patient information, and epidemiological data, present challenges in data storage, analysis, and interpretation for informed decision-making in clinical and public health settings.

Key Trends:

Shift towards Molecular Diagnostics

: There is increasing adoption of molecular diagnostic techniques such as PCR (Polymerase Chain Reaction), nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS) for rapid and accurate identification of pathogens and antimicrobial resistance markers.

Automation and Robotics

: Automation of microbiology testing processes, including specimen handling, culture, and susceptibility testing, is on the rise. Robotics and automated systems streamline workflows, improve turnaround times, and enhance laboratory efficiency.

Point-of-Care Testing (POCT)

: Expansion of point-of-care testing technologies for microbiology enables rapid diagnosis and treatment decisions at the bedside or in remote settings. POCT devices for infectious disease diagnostics are becoming more sophisticated and accessible.

Integration of Artificial Intelligence (AI)

: AI-driven algorithms are being integrated into microbiology testing platforms for data analysis, interpretation of complex microbial patterns, and prediction of antimicrobial resistance. AI enhances diagnostic accuracy, speeds up results, and supports personalized treatment approaches.

Advancements in Antimicrobial Susceptibility Testing (AST)

: Innovations in AST methodologies, including automated systems and rapid phenotypic testing, improve the precision of antimicrobial susceptibility profiles. These advancements aid in optimizing antibiotic therapy and combating antimicrobial resistance.

Rise of Multiplex Testing

: Multiplex assays capable of detecting multiple pathogens or resistance genes simultaneously are gaining popularity. These tests enhance diagnostic efficiency, reduce turnaround times, and support comprehensive infectious disease management.

Digitalization and Connectivity

: Digital solutions for microbiology laboratories, such as laboratory information management systems (LIMS) and electronic health records (EHRs), facilitate seamless data management, result reporting, and integration with healthcare systems for enhanced patient care.

Focus on Infectious Disease Surveillance and Epidemiology

: There is an increased emphasis on real-time infectious disease surveillance using microbiology data. Integration of genomic sequencing and epidemiological information aids in tracking disease outbreaks, monitoring trends, and implementing public health interventions.

Personalized Medicine Approaches

: Tailoring antimicrobial therapy based on individual patient characteristics, including genetic susceptibility and microbial profiles, is gaining traction. Microbiology testing plays a crucial role in guiding personalized treatment decisions and improving patient outcomes.

Global Microbiology Testing/Clinical Microbiology Market Regional Analysis

Here is a more detailed regional analysis of the global microbiology testing/clinical microbiology market:

North America

North America is significantly dominating the Microbiology Testing/Clinical Microbiology Market and is expected to continue its growth throughout the forecast period, owing to several variables.

North America boasts a highly developed healthcare infrastructure with modern facilities, sophisticated laboratories, and extensive networks of healthcare providers. This infrastructure supports the adoption and integration of advanced microbiology testing technologies.

The region is at the forefront of technological innovation in healthcare, including microbiology testing. North American companies and research institutions continually invest in and develop cutting-edge diagnostic tools, such as molecular diagnostics and next-generation sequencing (NGS), which enhance accuracy and efficiency in microbial identification.

North America has been an early adopter of advanced diagnostic technologies in clinical microbiology. This includes PCR (Polymerase Chain Reaction), mass spectrometry, and automated culture systems, which enable rapid and precise detection of pathogens and antimicrobial resistance.

The presence of leading academic institutions, research organizations, and pharmaceutical companies in North America fosters a robust R&D ecosystem. This ecosystem drives continuous innovation in microbiology testing methodologies, biomarker discovery, and therapeutic development related to infectious diseases.

The region has stringent regulatory standards and quality assurance measures governing clinical laboratories and diagnostic tests. Compliance with regulations such as CLIA (Clinical Laboratory Improvement Amendments) ensures high standards of testing accuracy, reliability, and patient safety.

North America commands a significant share of global healthcare spending, supporting substantial investments in healthcare technologies and infrastructure. The large market size encourages competition and drives innovation among microbiology testing providers to meet the diverse needs of healthcare institutions and patients.

Strong public health infrastructure and initiatives in North America emphasize the importance of infectious disease surveillance, outbreak detection, and response. Microbiology testing plays a pivotal role in these efforts, enhancing public health preparedness and response capabilities.

The region offers comprehensive educational and training programs for healthcare professionals, laboratory technicians, and microbiologists specializing in clinical microbiology. Continuous education and skill development ensure proficiency in using advanced diagnostic technologies and interpreting complex test results accurately.

Asia Pacific

Asia Pacific is experiencing growth in the Microbiology Testing/Clinical Microbiology Market. Asia Pacific countries have been increasing their healthcare expenditure significantly, fueling investments in healthcare infrastructure, including clinical laboratories and diagnostic facilities. This investment supports the expansion of microbiology testing capabilities.

The region faces a high burden of infectious diseases due to factors such as dense population centers, urbanization, and changing lifestyles. This drives demand for microbiology testing to accurately diagnose and manage infections.

Asia Pacific is increasingly adopting advanced microbiology testing technologies, including molecular diagnostics, next-generation sequencing (NGS), and automated systems. These technologies enable rapid and accurate detection of pathogens and antimicrobial resistance.

Improved awareness about the importance of early diagnosis and treatment of infectious diseases is increasing patient demand for microbiology testing services. Greater access to healthcare services and diagnostics is also contributing to market growth.

Governments and healthcare organizations in Asia Pacific are strengthening public health initiatives, including infectious disease surveillance and outbreak response. Microbiology testing plays a crucial role in these efforts by providing timely and accurate data for disease monitoring and control.

The region is witnessing rapid expansion of healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories. This infrastructure development supports the establishment of microbiology testing facilities and enhances diagnostic capacity.

Demographic shifts, such as aging populations and increasing urbanization, alongside changing epidemiological patterns, are driving demand for specialized microbiology testing services. These trends influence healthcare priorities and resource allocation in the region.

Emerging economies in Asia Pacific are experiencing robust economic growth, leading to increased healthcare spending and investments in healthcare technologies. This economic growth creates opportunities for market expansion and innovation in microbiology testing.

Global Microbiology Testing/Clinical Microbiology Market: Segmentation Analysis

The Global Microbiology Testing/Clinical Microbiology Market is segmented based on Product Type, Application, End-User, And Geography.

Microbiology Testing/Clinical Microbiology Market, By Product Type

• Instruments
• Reagents & Kits
• Consumables
• Software & Services

Based on Product Type, the Microbiology Testing/Clinical Microbiology Market is bifurcated into Instruments, Reagents & Kits, Consumables, Software & Services. The Instruments segment is significantly dominating the Microbiology Testing/Clinical Microbiology Market. This dominance is driven by increasing demand for advanced diagnostic technologies like automated microbial identification systems and PCR instruments, which offer rapid and accurate results, enhancing efficiency in microbiology testing processes and improving patient care outcomes.

Microbiology Testing/Clinical Microbiology Market, By Application

• Clinical Diagnosis
• Food Testing
• Pharmaceutical & Biotechnology Applications
• Environmental Testing

Based on Application, the Microbiology Testing/Clinical Microbiology Market is bifurcated into Clinical Diagnosis, Food Testing, Pharmaceutical & Biotechnology Applications, and Environmental Testing. The Clinical Diagnosis category is expected to dominate the Microbiology Testing/Clinical Microbiology Market. The high demand for microbiology testing in diagnosing infectious diseases remains a critical healthcare priority globally. The segment benefits from continuous advancements in diagnostic technologies and the increasing prevalence of infectious diseases worldwide.

Microbiology Testing/Clinical Microbiology Market, By End-Users

• Hospitals & Diagnostic Laboratories
• Food & Beverage Companies
• Pharmaceutical & Biotechnology Companies
• Environmental Testing Laboratories

Based on End-Users, the Microbiology Testing/Clinical Microbiology Market is bifurcated into Hospitals & Diagnostic Laboratories, Food & Beverage Companies, Pharmaceutical & Biotechnology Companies, and Environmental Testing Laboratories. The Hospitals & Diagnostic Laboratories segment is expected to lead the Microbiology Testing/Clinical Microbiology Market. The dominance stems from the consistent need for microbiology testing in clinical settings to diagnose and treat infectious diseases, supported by advanced healthcare infrastructure and increasing patient volumes requiring accurate and timely diagnostic results.

Microbiology Testing/Clinical Microbiology Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Global Microbiology Testing/Clinical Microbiology Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominates the Microbiology Testing/Clinical Microbiology Market. The advanced healthcare infrastructure, substantial healthcare expenditure, early adoption of advanced diagnostic technologies, stringent regulatory standards, and robust research and development activities, collectively drive market leadership in clinical microbiology.

Key Players

• The "Global Microbiology Testing/Clinical Microbiology Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
• Thermo Fisher Scientific Inc., bioMerieux SA, Danaher Corporation (Beckman Coulter), Becton, Dickinson, and Company (BD), Merck KGaA, Bruker Corporation, Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Inc., QIAGEN N.V., Charles River Laboratories International, Inc., Hologic, Inc., Luminex Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Microbiology Testing/Clinical Microbiology Market Key Developments

• In November 2022, IDEXX announced the acquisition of Tecta-PDS, a Canadian company known for introducing automation to water microbiology testing, focusing on parameters like E. coli and total coliforms. This acquisition enabled IDEXX to broaden its portfolio of water microbiology testing options, enhancing capabilities for both laboratory-based and field testing.
• In November 2022, Archer Daniels Midland (ADM) inaugurated a new microbiology laboratory at its ADM Specialty Manufacturing facility located in Decatur, Illinois. This expansion project doubled the facility's microbiology laboratory space and bolstered its testing capacities, supporting ADM's commitment to advanced microbiological analysis.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Microbiology Testing/Clinical Microbiology Market, By Product Type

• Clinical Diagnosis
• Food Testing
• Pharmaceutical & Biotechnology Applications
• Environmental Testing

5. Microbiology Testing/Clinical Microbiology Market, By Application

• Instruments
• Reagents & Kits
• Consumables
• Software & Services

6. Microbiology Testing/Clinical Microbiology Market, By End-User

• Hospitals & Diagnostic Laboratories
• Food & Beverage Companies
• Pharmaceutical & Biotechnology Companies
• Environmental Testing Laboratories

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Abbott Laboratories
• Becton, Dickinson and Company (BD)
• Danaher Corporation (through its subsidiary Beckman Coulter)
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Illumina, Inc.
• Merck KGaA, Darmstadt, Germany
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References